Definium Therapeutics
DFTX
190 hedge funds and large institutions have $241M invested in Definium Therapeutics in 2025 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 49 increasing their positions, 47 reducing their positions, and 21 closing their positions.
105% more call options, than puts
Call options by funds: $7.79M | Put options by funds: $3.8M
86% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 21
10% more funds holding
Funds holding: 172 → 190 (+18)
4% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.99% less ownership
Funds ownership: 56.6% → 54.61% (-2%)
17% less capital invested
Capital invested by funds: $289M → $241M (-$48.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$3.01M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.09M |
| 3 |
CC
Commodore Capital
New York
|
+$1.55M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.43M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TLP
Tri Locum Partners
New York
|
-$5.71M |
| 2 |
BlackRock
New York
|
-$2.54M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.27M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.32M |
| 5 |
Millennium Management
New York
|
-$1.29M |
DFTX Hedge Fund Activity: Q1 2025 in Review
190 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2025, worth a combined $241M — down 17% from $289M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new DFTX positions and 21 closed out — a net gain of 18 holders — while 49 added to existing stakes and 47 trimmed.
The largest buyer was Rosalind Advisors, opening a new position worth an estimated $3.01M. The largest seller was Tri Locum Partners, exiting entirely with an estimated $5.71M sold.
- 190 institutional investors held Definium Therapeutics (DFTX) as of Q1 2025, up from 172 in Q4 2024.
- Funds reported $241M of Definium Therapeutics stock for Q1 2025, down 17% quarter-over-quarter.
- 39 funds opened new Definium Therapeutics positions in Q1 2025 and 21 closed out, a net change of +18 holders.
- The largest Definium Therapeutics buyer in Q1 2025 was Rosalind Advisors, an estimated $3.01M added.
- The largest Definium Therapeutics seller in Q1 2025 was Tri Locum Partners, an estimated $5.71M sold.
Based on aggregated 13F filings for Q1 2025.